Current status and development of systemic therapies for metastatic renal clear cell carcinoma
10.3969/j.issn.1009-8291.2024.05.018
- VernacularTitle:转移性肾透明细胞癌的综合治疗现状与发展
- Author:
Ying LIU
1
;
Linhui WANG
Author Information
1. 海军军医大学第一附属医院泌尿外科,上海 200433
- Keywords:
metastatic renal clear cell carcinoma;
targeted therapy;
immunotherapy;
precision medicine;
combination therapy
- From:
Journal of Modern Urology
2024;29(5):466-470
- CountryChina
- Language:Chinese
-
Abstract:
With the continuous advancement of technology and the increasing understanding of metastatic renal cell carcinoma(mRCC),the treatment paradigm of mRCC has undergone significant transformation.Currently,in addition to surgery,mRCC is mainly treated with targeted therapy and immunotherapy,which have shown significant efficacy but also face challenges such as drug resistance and non-responsiveness persist.To address these issues,ongoing research and development of new technologies and drugs are under way.This article presents a comprehensive review of targeted therapy,immunotherapy,exploratory therapeutic options and treatment trends of mRCC.By summarizing the differences in technological principles and patient populations,it is argued that combination therapy and precision medicine will become the primary directions for future developments.Subsequent research will focus on optimizing the synergistic integration of diverse therapeutic techniques and achieving more precise patient stratification to realize more effective treatment.
